Literature DB >> 24891289

Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway.

Adam P Cribbs1, Alan Kennedy, Henry Penn, Jordan E Read, Parisa Amjadi, Patricia Green, Khaja Syed, Szymon W Manka, Fionula M Brennan, Bernard Gregory, Richard O Williams.   

Abstract

OBJECTIVE: Functionally impaired Treg cells expressing abnormally low levels of CTLA-4 have been well documented in rheumatoid arthritis (RA). However, the molecular defect underlying this reduced expression is unknown. The aims of this study were to assess the role of DNA methylation in regulating CTLA-4 expression in Treg cells isolated from RA patients and to elucidate the mechanism of their reduced suppressor function.
METHODS: CTLA-4 expression in Treg cells from RA patients and healthy controls was measured by quantitative polymerase chain reaction (PCR) and flow cytometry. Methylation of the CTLA-4 gene promoter was analyzed by bisulfite-specific PCR, followed by sequencing. Methylation-dependent transcriptional activity of the CTLA-4 gene promoter was measured by luciferase assay, and NF-AT binding to the CTLA-4 gene promoter was determined by chromatin immunoprecipitation. The role of CTLA-4 expression in controlling Teff cells was analyzed using an autologous mixed lymphocyte reaction.
RESULTS: Down-regulation of CTLA-4 expression in Treg cells from RA patients was caused by methylation of a previously unidentified NF-AT binding site within the CTLA-4 gene promoter. As a consequence, Treg cells were unable to induce expression and activation of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO), which in turn resulted in a failure to activate the immunomodulatory kynurenine pathway.
CONCLUSION: We show for the first time that epigenetic modifications contribute to defective Treg cell function in RA through an inability to activate the IDO pathway. Therefore, this study sets a precedent for investigating potential therapeutic strategies aimed at reinforcing the IDO pathway in RA patients.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24891289     DOI: 10.1002/art.38715

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  51 in total

Review 1.  Epigenetics in the pathogenesis of RA.

Authors:  Caroline Ospelt; Steffen Gay; Kerstin Klein
Journal:  Semin Immunopathol       Date:  2017-03-21       Impact factor: 9.623

Review 2.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

Review 3.  The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases.

Authors:  A Mohr; M Atif; R Balderas; G Gorochov; M Miyara
Journal:  Clin Exp Immunol       Date:  2019-03-24       Impact factor: 4.330

4.  Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.

Authors:  Giada Mondanelli; Alice Coletti; Francesco Antonio Greco; Maria Teresa Pallotta; Ciriana Orabona; Alberta Iacono; Maria Laura Belladonna; Elisa Albini; Eleonora Panfili; Francesca Fallarino; Marco Gargaro; Giorgia Manni; Davide Matino; Agostinho Carvalho; Cristina Cunha; Patricia Maciel; Massimiliano Di Filippo; Lorenzo Gaetani; Roberta Bianchi; Carmine Vacca; Ioana Maria Iamandii; Elisa Proietti; Francesca Boscia; Lucio Annunziato; Maikel Peppelenbosch; Paolo Puccetti; Paolo Calabresi; Antonio Macchiarulo; Laura Santambrogio; Claudia Volpi; Ursula Grohmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-05       Impact factor: 11.205

5.  Therapy: Arming the regulators - new strategies to treat autoimmunity.

Authors:  Richard O Williams; Wen-Yi Tseng
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 6.  The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.

Authors:  K Schinnerling; J C Aguillón; D Catalán; L Soto
Journal:  Clin Exp Immunol       Date:  2017-04-20       Impact factor: 4.330

7.  CTLA-4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis.

Authors:  Katrin Klocke; Rikard Holmdahl; Kajsa Wing
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

8.  IDO1 and TGF-β Mediate Protective Effects of IFN-α in Antigen-Induced Arthritis.

Authors:  Jaya Prakash Chalise; Maria Teresa Pallotta; Sudeep Chenna Narendra; Björn Carlsson; Alberta Iacono; Joanitah Namale; Louis Boon; Ursula Grohmann; Mattias Magnusson
Journal:  J Immunol       Date:  2016-09-19       Impact factor: 5.422

9.  Rheumatoid arthritis: Who knows why regulatory T cells are defective in RA ... IDO.

Authors:  Nicholas J Bernard
Journal:  Nat Rev Rheumatol       Date:  2014-06-17       Impact factor: 20.543

Review 10.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.